This phase 2/3 BFAST trial (NCT03178552) evaluated entrectinib in treatment-naive patients with ROS1-positive NSCLC identified solely by liquid biopsies. The trial met its primary endpoint, demonstrating a confirmed objective response rate (ORR) of 81.5% (95% CI: 68.6–90.8), consistent with results from a tissue-based analysis of entrectinib. The safety profile was consistent with previous reports. These findings support the use of liquid biopsies for clinical decision-making in advanced NSCLC.
Publisher
Nature Medicine
Published On
Jul 01, 2024
Authors
Solange Peters, Shirish M. Gadgeel, Tony Mok, Ernest Nadal, Saadettin Kilickap, Aurélie Swalduz, Jacques Cadranel, Shunichi Sugawara, Chao-Hua Chiu, Chong-Jen Yu, Mor Moskovitz, Tomohiro Tanaka, Rhea Nersesian, Sarah M. Shagan, Margaret Maclennan, Michael Mathisen, Vijay Bhagawati-Prasad, Cheick Diarra, Zoe June Assaf, Venice Archer, Rafal Dziadziuszko
Tags
entrectinib
ROS1-positive NSCLC
liquid biopsies
response rate
clinical decision-making
Related Publications
Explore these studies to deepen your understanding of the subject.
